Adverse events588

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 588

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk
other	Diarrhoea	Gastrointestinal disorders	Double-blind Phase: TAF 25 mg	35	581
other	Diarrhoea	Gastrointestinal disorders	Double-blind Phase: TDF 300 mg	19	292
other	Diarrhoea	Gastrointestinal disorders	Open-label TAF Extension Phase: TAF 25 mg to TAF 25 mg	13	514
other	Diarrhoea	Gastrointestinal disorders	Open-label TAF Extension Phase: TDF 300 mg to TAF 25 mg	6	253
other	Dyspepsia	Gastrointestinal disorders	Double-blind Phase: TAF 25 mg	32	581
other	Dyspepsia	Gastrointestinal disorders	Double-blind Phase: TDF 300 mg	16	292
other	Dyspepsia	Gastrointestinal disorders	Open-label TAF Extension Phase: TAF 25 mg to TAF 25 mg	16	514
other	Dyspepsia	Gastrointestinal disorders	Open-label TAF Extension Phase: TDF 300 mg to TAF 25 mg	9	253
other	Gastrooesophageal reflux disease	Gastrointestinal disorders	Double-blind Phase: TAF 25 mg	19	581
other	Gastrooesophageal reflux disease	Gastrointestinal disorders	Double-blind Phase: TDF 300 mg	10	292
other	Gastrooesophageal reflux disease	Gastrointestinal disorders	Open-label TAF Extension Phase: TAF 25 mg to TAF 25 mg	17	514
other	Gastrooesophageal reflux disease	Gastrointestinal disorders	Open-label TAF Extension Phase: TDF 300 mg to TAF 25 mg	13	253
other	Nausea	Gastrointestinal disorders	Double-blind Phase: TAF 25 mg	35	581
other	Nausea	Gastrointestinal disorders	Double-blind Phase: TDF 300 mg	15	292
other	Nausea	Gastrointestinal disorders	Open-label TAF Extension Phase: TAF 25 mg to TAF 25 mg	5	514
other	Nausea	Gastrointestinal disorders	Open-label TAF Extension Phase: TDF 300 mg to TAF 25 mg	2	253
other	Fatigue	General disorders	Double-blind Phase: TAF 25 mg	36	581
other	Fatigue	General disorders	Double-blind Phase: TDF 300 mg	14	292
other	Fatigue	General disorders	Open-label TAF Extension Phase: TAF 25 mg to TAF 25 mg	6	514
other	Fatigue	General disorders	Open-label TAF Extension Phase: TDF 300 mg to TAF 25 mg	5	253

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01940471/events

API reference For AI assistants

Adverse events588

Sources 3

Read this list from software.